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B lymphocytes originate from pluripotent hematopoietic stem cells and differ-
entiate into antibody-secreting cells through multistep differentiation stages,
such as pre-B cells, immature B cells with surface IgM, and mature B cells with
surface IgM and IgD . A number of human B cell antigens have been defined by
inAbs (I-10) . However, most B cell-specific mAbs, except for antibodies against
plasma cells (5) and activated B cells (9, 10), are known to recognize cells of the
B lineage at a wide range of differentiation stages from pre-B cells to mature B
cells . It has therefore been difficult to identify B cells at a specific differentiation
stage by using such B cell-specific mAbs .
Several previous studies (11-14) have shown the expression of FcER on a
certain percentage (1-5%) of circulating B or T cells using the rosette method
with IgE-conjugated ox red blood cells (ORBC) . t Our previous study (15) with
FcER-specific mAbs with several different epitope specificities showed that >50%
of circulating B cells express FcER on their surface, while T cells do not display
this receptor, even with T cells from patients with hyper-IgE syndrome . The
discrepancy in the results may be due to the difference in the sensitivity of the
assay system and the antibodies used . In the present study, the distribution of
FcER+ cells was studied in various lymphoid tissues, and the results show that
FcER is a B cell-specific phenotype marker, the expression of which is strictly
correlated with the differentiation stage of B cells, especially with the isotype
switching in B cells .
Materials and Methods
Antibodies . Human IgE(PS) was the same preparation as described previously (16) .
Human IgGI myelomaprotein was kindly given by Dr . A. Shimizu (Osaka MedicalCenter
and Research Institute for Maternal and Child Health, Osaka, Japan) . FITC-conjugated
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' Abbreviations used in this paper:
￿
AT, ataxia teleangiectasia ; B-BCGF, B cell-derived B cell
growth factor; BCDF, B cell differentiation factor; BSF-1, B cell stimulatory factor 1 ; CV1, common
variable immunodeficiency ; MNC, mononuclear cell ; ORBC, ox red blood cell; PC, phycocyanin ;
PHA-sup, supernatant from cultures of T cells stimulated with PHA; PI, propidium iodide ; TR,
Texas red .
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F(ab)'2 fragment ofgoat anti-human IgD and FITC-F(ab)'2 fragment of goat anti-human
IgA were purchased from Tago Inc. (Burlingame, CA). FITC-anti-B1 was from Coulter
Immunology (Hialeah, FL) . An anti-human IgM mAb was a kind gift from Dr. M . Sugi
(Yamasa Shoyu Co., Ltd, Tokyo, Japan). An anti-human IgE mAb was the same prepa-
ration as described previously (17). The anti-FcER mAbs 1-7, 3-5, and 8-30, which are
of IgG2b, IgG 1, and IgM, respectively, were produced by hybridization ofP3U 1 myeloma
with spleen cellsfrom BALB/c mice immunized with RPMI-8866 cells (15). Two antibod-
ies (1-7 and 8-30) recognized the epitope close to IgE-binding site of Fc(R and blocked
IgE binding to 8866 lymphoblastoid cells. The antibody 3-5 recognized a different
epitope on FccR, and could not block IgE binding to 8866 cells. These antibodies
precipitated 25,000 and 46,000 Mr polypeptides under reducing and nonreducing con-
ditions. The mAbs were purified from ascites by 50% saturated ammonium sulfate
precipitation followed by gel filtration using Sepharose 6 B (Pharmacia Fine Chemicals,
Uppsala, Sweden) for IgM class, or by ion-exchange chromatography using QAE-Sephadex
(Pharmacia Fine Chemicals) for IgGI and IgG2b classes. Some of the antibodies were
conjugated with biotin or FITC as described (18, 19). Some of the antibodies were also
labeled with phycocyanin (PC) by crosslinking with sulfosuccinimydyl 4-(p-maleimido-
phenyl) butylate (Pierce Chemical Co., Rockford, IL) as described (20).
Factor Preparations.
￿
As conventional T cell factors, partially purified culture super-
natants from PHA-stimulated tonsillar T cells were used (21). Briefly, tonsillar T cells
were cultured at 106 cells/ml with 0.1% PHA (Difco Laboratories, Detroit, MI) for 48 h
and the supernatant was collected. The concentrated supernatant was fractionated by
HPLC gel filtration, and a fraction with an M, of ^-20,000 was used as a source of T cell
factor(s). This preparation contains B cell stimulatory factor 1 (BSF-1), B cell differentia-
tion factor (BCDF or BSF-2), and IL-2 activities. BCDF has been purified to homogeneity
as described (22). Purified BCDF induced Ig secretion in Staphylococcus aureus Cowan I-
stimulated B blast cells at 1 pM concentration, but did not have growth activity (22). B
cell-derived B cell growth factor (B-BCGF) was obtained from the culture supernatant of
RPMI-1788 lymphoblastoid cells (23). The B-BCGF induced the proliferation in anti-,,-
activated human B cells at a concentration of 10% (vol/vol).
Recombinant Lymphokines.
￿
rIL-2 was a kind gift from Dr. J. Hamuro (Ajinomoto Co.,
Ltd., Tokyo, Japan). rIFN-a and rIFN-,y were kindly provided from Kyowa Hakko Co.,
Ltd., Tokyo, Japan. rIL-1 was kindly provided from Dr. Y. Hirai, (Otsuka Pharmaceutical
Co., Ltd., Tokushima, Japan).
Preparation of Human Mononuclear Cells (MNC).
￿
PBL were obtained from normal
donors and patients with hyper-IgE syndrome or immunodeficiencies. Tonsillar MNC
were obtained from patients with chronic tonsillitis. Bone marrow MNC were obtained
from the pelves of immunologically normal donors. MNC were prepared by Ficoll-
Hypaque (Pharmacia Fine Chemicals) gradient centrifugation. In some experiments, B
cells were prepared by rosetting with (2-aminoethyl)isothiouronium bromide (Aldrich
Chemical Co., Milwaukee, WI)-treated SRBC .
Patients with Immunodeficiencies or Hyper-IgE Syndrome.
￿
Blood samples of patients with
common variable immunodeficiency (CVI) or ataxia teleangiectasia (AT) were kindly
provided by Drs. K. H. Pyun, H. D. Ochs (University of Washington, Seattle, WA) and
Dr. K. Kawa-Ha (Osaka University, Osaka, Japan). Serum Ig levels of these patients were
the following; CVI-I (IgG, 340 mg/dl; IgM, 55 mg/dl; IgA, <7 mg/dl), CVI-2 (IgG, 230
mg/dl ; IgM, 18 mg/dl; IgA, 14 mg/dl; IgE, 19 IU/ml), CVI-3 (IgG, 181 mg/dl; IgM, 10
mg/dl ; IgA, 10 mg/dl), AT-1 (IgG, 1,350 mg/dl; IgM, 320 mg/dl; IgA, 0 mg/dl), and
AT-2 (IgG, 300 mg/dl; IgM, 10 mg/dl; IgA, 0 mg/dl). Blood samples of patients with
hyper-IgE syndrome were kindly provided by Drs. K. H. Pyun, H. D. Ochs, and Y. Iikura
(National Children Hospital, Tokyo, Japan). These patients showed suppressed neutrophil
chemotaxis, recurrent infections, and high serum IgE levels (6,000-104,000 IU/ml).
Two-colour Immunofuorescence Analysis.
￿
To remove cytophilic Igs, cells were treated
with acetate buffer (0.05 M, pH 4.0) containing 0.085 M NaCl, 0.005 M KCI, and 1
FCS for 1 min on ice (24), and then washed with staining buffer (RPMI 1640 minus
biotin, riboflavin, and phenol red; 2% FCS, 10 mM Hepes, 0.1 % NaN3). 106 cells wereKIKUTANI ET AL.
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incubated with FITC-conjugated or biotinylated antibodies for 20 min in a flexible 96-
well microtiter plate in the first step, washed three times with staining buffer, then
incubated with Texas red (TR)-avidin for 20 min in the second step and washed three
times with staining buffer . Propidium iodide (PI) (10 wg/ml) was included in the last 5
min of the second step to label dead cells. All antibodies except for biotinylated human
IgG and IgE were used at the concentrations that gave maximal fluorescence intensities
without nonspecific binding. Biotinylated human IgE and IgG were used at 300 Ag/ml
because of low binding affinity of the receptors on lymphocytes, moreover, this concen-
tration could not saturate Fcy and Fce receptors. Stained cells were analyzed on a FACS
440 equiped with both argon ion laser operating at 488 nm generating forward scatter,
fluorescein, PI, and large-angle (obtuse) scatter signals, and a second argon laser pumping
an orange dye laser circulating rhodamine 6G tuned to emit 595-nm light to excite TR
(25). All fluorescein channels and large-angle scatter were amplified logarithmically with
a range of either four decade (for fluorescence) or two decade (obtuse scatter). List-mode
data were collected on 20-50 X 10' cells for each sample and analyzed on a Vax 11/730
computer using programs originally developed at Stanford University. Histograms rep-
resent the relative number ofcellsas a function offluorescence intensity within a particular
gated population. Contour plots represent the correlated expression of two surface
antigens by showing peak linesenclosing equal percentages ofcellswith the two-parameters
distribution .
Induction ofFCeR Expression.
￿
Bone marrow MNC, sorted cells, or PBL from a patient
with CVI were cultured at 5 X 105 cells/ml in a 96-well microtiter plate for 3 d in the
presence or absence of 10 jAg/ml IgE or IgG with or without PHA supernatant (10%
vol/vol) or recombinant or purified lymphokines. After 3 d of culture, the cells were
stained with FITC-anti-B1 and biotinylated anti-FceR antibodies, followed by incubation
with TR-avidin, and analyzed by FACS.
Results
Expression of FceR on Human B Lymphocytes from PBL, Tonsils, and Bone
Marrow. Anti-FceR mAbs 1-7 (1'2b), 3-5 ('Y,), and 8-30 (A), have been prepared
by using RPMI-8866 cells as immunizing antigen. In an earlier study (15), it was
shown that two mAbs (1-7 and 8-30) recognized the same epitope of FceR and
inhibited the binding of IgE with 8866 cells, while mAb 3-5 recognized a
different epitope of FceR and did not inhibit the IgE binding. However, all these
mAbs could precipitate 25,000 and 46,000 M, polypeptides under reducing and
non-reducing conditions (15). By using these mAbs, the distribution of FceR+
cells in various lymphoid tissues, such as PBL, tonsils, and bone marrow, was
examined. Because the three mAbs showed the same results, mAb 8-30 was used
in all the experiments. MNC from various lymphoid tissues were stained with
FITC-anti-B1 and biotinylated anti-FceR followed by TR-avidin and analyzed by
dual-laser FACS . As described in Table I, FceR was expressed on most Bl + B
cells in PBL, and approximately one-half of B1 + B cells derived from tonsils. On
the other hand, only a small fraction of B1 + B cells were positive for the FceR
expression in bone marrow. It is noteworthy that B1 - cells did not express FceR
in any of the lymphoid tissues tested. The variability in the frequency of FceR+
cells in PBL, tonsils, and bone marrow suggests that FceR may be expressed on
B cells at a certain defined differentiation or activation stage.
Correlation of FceR Expression and Ig Isotypes on B Cells.
￿
Tonsillar MNC were
stained with anti-FceR and with conjugates directed against different Ig isotypes.
As shown in Fig. 1 A, FceR was expressed on most A and S positive B cells in
tonsils . On the other hand, almost all -y- or a-bearing B cells, which were1458
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TABLE I
Expression ofFccR on B Cellsfrom Peripheral Blood, Tonsils, and
Bone Marrow
PBL from five donors, tonsillar MNC from five donors, and bone
marrow MNC from three donors were stained with FITC-anti-B1 and
biotinylated anti-FceR, developed with TR-avidin and analyzed by
FACS. Mean percentage of FceR+ cells ± SD.
* Mean percentage of FceR'cellsamongB1'or B1 - cells, assayed by two-
coloranalysis as describedin Materials and Methods.
abundantly observed in tonsils, did not express FceR on their surface. Other
experiments were conducted to study whether Fc7R expression was also corre-
lated with the isotype expression as observed with the FCER. Several reports (26-
28), have shown that FcyR and FceR could be detected by flow-cytometric
analysis of cells stained with monomeric IgG or IgE. Since antibodies specific to
human FcyR were not available, biotinylated IgE and IgGI were used for the
comparison of the expression of FcyR and FceR on +,5+ B cells, and on y+ or
a+ B cells. As shown in Fig. 1 A and B, the specificity ofthe bindingofbiotinylated
IgE was almost comparable to that of the anti-FceR antibody, in fact, the IgE-
binding was observed on A+,5+ B cells, but not on y+ or a+ B cells. ^-50% of ,u+
or b+ cells could notbind IgE, although they were stainedwith anti-FceRantibody.
This may be due to the difference in the affinity of IgE and anti-FceR antibody
with FceR . On the other hand, IgGI-binding cells were observed in U-,5- B cells
as well as Fc+,b+ B cells. For example, almost all a+ B cell could bind IgGI . The
results indicate that the FcyR expression was not correlated with Ig isotype
expression .
Most peripheral blood B cells were j+,5+, and this may explain why most B1+
cells in PBL are positive for the FceR expression, while only 50% of tonsillar B
cells were positive for this marker. It is therefore difficult to analyze the
expression of FcER on y+ or a+ B cells in PBL on the contour plot because of
the paucity of these cells. Fig. 2 shows the histograms of the FcER expression on
a+ 'U+ y+ and a+ B cells in PBL. Most 5+ (Fig. 2 A) or ,u+ (B) B cells expressed
FCER, as in the case of tonsillar B cells. However, y+ (Fig. 2 C) or a+ (D) B cells
did not express FCER, although a small fraction of these cells showed weak
expression . The results show that FccR is preferentially expressed on circulating
S+ and u+ B cells, but not on y+ or a+ B cells; this may explain why PBL include
more FccR+ cells than found in tonsils.
Because of the paucity of E-bearing B cells in PBL or tonsils, the expression of
FcER on E+ B cells could not be examined . Therefore, PBL from patients with
hyper-IgE syndrome were studied. Fig. 3 shows the representative results ob-
served in PBL from two patients with hyper-IgE syndrome . In fact, the FcER
expression was augmented in A,+ or S+ B cells in these patients compared to that
in normal individuals (Fig. 3, A and B). However, y+ or a+ B cells did not express
Cell source
Total
FceR*cells (%)
B1*cells* B1- cells*
PBL 11 .2 ± 3.1 87 ± 5.2 <0.1
Tonsils 28.4 ± 7.4 51 ± 11 .3 <0.1
Bone marrow 0.5 ± 0.2 3.0 ± 1.2 <0.1KIKUTANI ET AL .
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Fluorescence intensity
FIGURE 2.
￿
FccR expression on various isotype-positive B cells from normal PBL. PBL from
a normal individual were doubly stained with biotinylated anti-FceR and FITC-anti-IgD, PC-
anti-IgM, PC-anti-IgG, or FITC-anti-IgA. The fluorescence intensities of FceR staining of
IgD+ (A), IgM+ (B), IgG+(C), or IgA' (D) B cells are shown on the histograms. The limit of
background fluorescence level is indicated with dotted perpendicular line.
FceR even in PBL from patients with hyper-IgE syndrome (Fig. 3, C and D). It
is worth noting that the FcER expression was not observed in E' B cells (Fig. 3
E) . All of these results indicate that the FccR expression is observed only on
mature A',S' cells, and the expression is lost after the isotype switching from
9+,5+ B cells to y+, a+, or E' B cells occurs.
Induction ofFLER in Bone Marrow and Tonsillar B Cells.
￿
As described in Table
I, p.+,5+ B cells in PBL were FcER+, while B cells in bone marrow were FcER-,
suggesting that only circulating mature B cells are able to express FcER. More-
over, experiments were conducted to study whether FccR could be induced in
bone marrow B cells by certain factors. As shown in Fig. 4, T cell-derived PHA-
conditioned medium (PHA-sup) could induce the FccR expression on 131' B cells
(Fig. 4 A), particularly on S+ B cells (Fig. 4 B). The addition of IgE but not IgG
could augment the PHA-sup-induced expression of FcER. However, IgE alone,
without PHA-sup, showed no effect on FcER expression .
As described earlier, circulating 6- B cells, which are mainly a' or y+, do notFluorescence intensity
KIKUTANI ET AL.
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FIGURE 3.
￿
FCER expression on various isotype-positive cellsfrom PBL ofpatients with hyper-
IgE syndrome. PBL from two hyper-IgE patients were doubly stained with biotinylated anti-
FceR and FITC-anti-IgD, PC-anti-IgM, PC-anti-IgG, FITC-anti-IgA, or PC-anti-FceR and
biotinylated anti-IgE. Biotinylated antibodies were developed with TR-avidin or FITC-avidin.
The fluorescence intensities of FcER staining of IgD` (A), IgM+ (B), IgG+ (C), IgA* (D), or
IgE' (E) Bcells are shown on the histograms. Solid anddotted linesrepresent the histogramss
of PBL from each of two patients.
express FcER . To study whether FCER is inducible in those cells, S- B cells were
sorted from tonsillar B cells and incubated with PHA-sup and IgE. As shown in
Fig. 5 A, stimulation did not induce expression of FcER on circulating S- B cells,
indicating that the loss of the FcER expression was irreversible in the cells that
had already completed isotype switching. A small fraction of 8+ B cells in tonsil
did not express FcER. However, as shown in Fig. 5 B, PHA-sup plus IgE could
induce the FcER expression in these cells, suggesting that they may be in an
immature stage of differentiation. Therefore, these results indicate that there
are two different varieties of FcER- B cells: immature B cells, and B cells that
had already switched to other isotypes.
Lymphokine(s) Responsible for FcER Expression.
￿
To examine the nature of
Lmphokine(s) responsible for the induction of FcER, bone marrow MNC were
cultured with recombinant or highly purified lymphokines in the presence of
IgE. As shown in Fig. 6, none of the recombinant or purified lymphokines,
including IL-1 (Fig. 6 B), IL-2 (C), IFN-,Q (D), IFN-y (E), and BCDF (F) and
crude B-BCGF (Fig. 6 G) induced the expression of FCER. A mixture of these
lymphokines (Fig. 6 H) also failed to induce the FCER expression. On the other
hand, PHA-sup (Fig. 61) could induce the FcER expression in more than half of
the bone marrow B cells. As shown (Fig. 6j), IFN-y almost completely abrogated1462
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Fluorescence intensity
FIGURE 4.
￿
Induction of FcER on bone marrow B cells. Bone marrow MNC from an immu-
nologically normal adult donor were incubated without (-) or with IgE (10 jug/ml), PHA-sup
(10% vol/vol), PHA-sup plus IgG (10 ug/ml), or PHA-sup plus IgE, for 3 d. After culture,
cells were doubly stained with biotinylated anti-FceR andFITC-anti-B1 or FITC-anti-IgD, and
developed with TR-avidin. Cells were analyzed by FACS. The intensities of FceR staining on
Bl' Bcells (A)and IgD* B cells (B) were shown in the histogram.
Fluorescence intensity
FIGURE 5.
￿
FcER can be induced on 6' cells but not S- cells in tonsils. Tonsillar B cells were
stained with anti-FceR and anti-IgD and S-, FceR- (A) and S', FceR- (B) cells were sorted by
FACS. Sorted cells were incubated with (solid line) or without (dashed line) PHA-sup (10%
vol/vol) and IgE (10 Kg/ml) for3 d, and stained with anti-FceR andanti-B1 . Theintensities of
FcER staining of Bl' B cells were shownin the histograms.
the induction of the FcER expression by PHA-sup. Since it is known (29) that
IFN-y inhibits the BSF-1 activity in the activation of murine B cells, it may be
possible that BSF-1-like activity is involved in the induction of FceR expression,
although the human counterpartof murine BSF-1 has not yetbeen characterized.
Failure ofFceR Expression on Lymphocytesfrom Patients with Certain Immunode-
ficiencies. PBL from patients with AT or CVI were stained with anti-FcER and
anti-B1 or anti-IgM and anti-IgD and analyzed by FACS. Three cases of CVIKIKUTANI ET AL. 1463
FIGURE 6.
￿
Lymphokine(s) responsible for the induction of FcfR. Bone marrow MNC were
incubated in thepresence of IgE (10 hg/ml), without (A), or with rIL-1 (150 U/ml) (B); HL-2
(150 U/ml) (C); rIFN-S (10' U/ml) (D); rIFN-,y (10' U/ml)(E); purified BCDF (50 U/ml)(F);
crude B-BCGF (10% vol/vol) (G);a mixture of IL-1, IL-2, IFN-fl, IFN-y, BCDF,and B-BCGF
(H); PHA-sup(10% vol/vol) (I);and PHA-supplus IFN--y(10' U/ml) (f). After 3dincubation,
cells were stained with anti-FceR and anti-B1 and analyzed by FACS. The intensities of FcfR
staining of B1' B cells are shown in the histograms.1464
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TABLE II
Failure ofFcER Expression on Lymphocytesfrom
Immunodefciency Patients
PBL from patients with CVI or AT were stained with antibodies against
B 1, IgD, IgM, or FcER and analyzed by FACS. Percentages of positive
cells were shown.
* Cells were stained with FITC-anti-B1 and biotinylated anti-FCER, and
analyzed by FACS. The percentages of FcER+ cells among B 1+cells were
assayed by two-color analysis with FACS as described in Materials and
Methods.
Ruorescence intensity
FIGURE 7 .
￿
FcER is inducible on FCER- PBL from a patient with CVI . PBL from a patient
with CVI were incubated without (A) or with (B) PHA-sup (10% vol/vol) or PHA-sup and IgE
(10 pg/ml) (C) for 3 d. After incubation, cells were stained with anti-FcER and anti-BI and
analyzed by FACS . The intensities of FcER staining of B1* B cells are shown in the histograms.
and two cases of AT were studied, and the results are summarized in Table II.
In all these cases, most of the B cells expressed both IgM and IgD, although
some patients had few B cells. It was interesting to note that >90% of Bl + B
cells in all these patients did not express FceR. The results suggest that B cells
from these patients are similar in their differentiation stage to /,+,5+ B cells found
in the bone marrow rather than in PBL. The results furthermore suggest a
possible arrest in the maturation of these B cells. To study whether FcER could
be induced by external signals, PBL from a patient with CVI (CVI-1) were
cultured with PHA-sup and IgE for 3 d, and the FcER expression on B1 + B cells
was examined. As shown in Fig. 7 B, PHA-sup could induce FcER expression in
a certain fraction of those B cells, and the addition of IgE could augment the
expression (Fig. 7 C), suggesting that those B cells are in a similar differentiation
stage as that of bone marrow B cells.
Antigen
Percentage of
CVI-1 CVI-2
positively staining cells
CVI-3 AT-1
from:
AT-2
B1 20 2.5 4 30 5
IgD 17 1 .8 2 27 2
IgM 19 2.3 3.6 28 4.5
FcER 0.5 0.1 0.2 0.8 0.05
FcER, B1* 2 .5 4 5 2.4 1.0KIKUTANI ET AL.
Bone Marrow
￿
PBL and Tonsils
IgM* ￿IgM * IgD+ ￿IgM'IgD'
￿
IgG*, IgA` or IgE`
Fct-R- Fct-R Fct-R' Fct-R
(inducible)
￿
(not inducible)
FIGURE 8 .
￿
A scheme for the correlation of the FCeR expression and human Bcell differen-
tiation.
Discussion
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The present study shows that FccR is a B cell-specific surface molecule, the
expression of which is strictly correlated with the differentiation stage of B cells:
(a) bone marrow B cells with surface IgM and IgD do not express FceR, although
its expression could be induced; (b) circulating B cells with surface IgM and IgD
express FcER; but (c) circulating B cells with no surface IgD, which have already
undergone isotype switching into IgG-, IgA-, or IgE-bearing cells, do not express
and can not be induced to express FcER. Therefore, according to these obser-
vations, the differentiation of B cells can be divided into three stages as described
in Fig. 8: (a) y+,b+ FCER- bone marrow B cells, (b) A+,b+ FccR+ circulating B cells,
and (c) A-,b- FceR- with y+, «+, or E+ B cells.
These results show that the majority of circulating u+b+ B cells express FcER,
and this is in marked contrast with several previous studies (11-14) in which it
was reported that only a few percent of Fc(-R+ cells were detected in PBL by the
rosette method with IgE-conjugated ORBC. The discrepancy may be due to the
difference in sensitivity between the assay systems used. It is important to note
that the FcER found on the surface of lymphocytes are of relatively low affinity
compared with the homologous receptors on mast cells and basophils (30), and
thereforethe use ofhighly specific mAbs has helped in monitoring the expression
of FCER. In the present study, the expression of FcER was restricted to B1 + cells
even after induction. This is in marked contrast with previously reported studies
(13, 26). Therefore, the specificity of the mAbs, used should be confirmed. The
specificity ofthe anti-FcERantibodies has been extensively studied in our previous
report (15). The mAb 8-30 was shown to recognize FcER+ B cell lines such as
RPMI-8866 and CESS, butnot a Fc(R- B cell line, Daudi. The antibody inhibited
IgE binding to 8866 cells. The mAb 3-5 had the same staining pattern with 8-
30, but did not inhibit the IgE binding. However, two-color FACS analysis
showed a correlated expression of the molecules recognized by these mAbs, on
B cells or B cell lines. Furthermore, both mAbs (8-30 and 3-5) precipitated
surface molecules with Mr 45,000 and 25,000, and preabsorption of the cell
lysates with mAb 8-30 removed the molecules reactive with mAb 3-5. Further-
more, we have recently (Owaki et al . manuscript submitted for publication)
established mouse L cell transformants that selectively express the human IgE
receptor recognized by its ability to bind human IgE and the mAbs used in this
study. The receptor on the L cell transformants has been detected both by IgE-
ORBC rosetting and FACS analysis . The mAbs did not react with granulocytes
fraction of PBL (data not shown) . All of these results indicated that these two1466
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mAbs (8-30 and 3-5) recognized different epitopes of the same FcER on B
lymphocytes. The results obtained either with 8-30 or 3-5 were identical with
regards to the expression of FCER on various B cells. The results obtained with
biotinylated IgE were also identical with those observed with the mAbs. In the
staining with biotinylated IgE, >300 Ag/ml IgE could not saturate the receptors.
Therefore, thepresent results indicate that the lymphocyte FCER with low affinity
is a B cell-specific differentiation marker. The discrepancy between our and
several other results (11-14, 26) cannot be explained at the present time.
A number of B cell-specific mAbs have been reported. However, surface
molecules recognized with most of these antibodies are expressed on B-lineage
cells in a wide range of differentiation stages, including immature bone marrow
and mature B cells. None of the mAbs so far reported could differentiate bone
marrow B cells and circulating B cells, as demonstrated using anti-FcER and
presented in this study. Some of the earlier reported antibodies, however, could
react only with activated B cells (9, 10), B blasts (31, 32) or plasma cells (5). In
previous studies (10, 33), we prepared a mAb (anti-Ba) that could recognize
activated B cells but not resting B cells. Anti-FcER could react with both Ba- and
Ba+ cells in PBL and tonsils (data not shown), and activation of resting B cells
with anti-IgM or phorbol ester did not augment or abrogate the FCER expression
(data not shown). The results show that the expression of FcER is not correlated
with the activation stage of mature B cells, but rather is related to the differen-
tiation stage of B-lineage cells.
The expression of FCER was inducible in bone marrow B cells with PHA-sup.
However, recombinant IL-2, IL-1, IFN-y, IFN-a, and purified BCDF did not
show any effect on the expression of FcER. PHA-sup used herein probably
contains BSF-1-like activity, since it showed a strong synergy with anti-Fe for the
proliferation of Ba- resting B cells (33). Therefore, a possible candidate respon-
sible for the FCER induction maybe BSF-1 (34, 35). Furthermore, the observation
that IFN-y could completely inhibit the FCER expression induced by PHA-sup
strongly suggests that the human counterpart of BSF-1 may be responsible for
FCER induction, since IFN-y is known to inhibit the effect of BSF-1 in the
activation of murine resting B cells (29).
The induction of FcER in bone marrow B cells was augmented by the addition
of IgE but not IgG. This may explain the augmented expression of FcER on B
cells of patients with hyper-IgE syndrome. A recent study (36) with murine B
cells showed that BSF-1 could augment the production of IgE. Therefore, it
might be possible that the overproduction of BSF-I could be responsible for the
augmented expression of FcER as well as for the high serum concentration of
IgE in hyper-IgE syndrome. In contrast, B cells from patients with CVI or AT
did not express any FCER, suggesting possible maturational arrest of B cells.
PHA-sup could induce the FcER expression in these defective B cells, strongly
suggesting that B cells in these patients are at a similar differentiation stage as
A+,8+ B cells found in the bone marrow of normal individuals. Two alternative
possibilities should be considered with regards to their defect: (a) the defect is
intrinsic in B cells, and the latter may not be sensitive enough to signals delivered
by helper T cells, or (b) the defect may be in the regulatory function of T cells,
and the appropriate signals required for the acquisition of FcER may not beKIKUTANI ET AL.
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available or could not be delivered. The second possibility seems to be unlikely,
since PHA-sup from T cells of patients could induce FCER expression on normal
bone marrow B cells (data not shown) .
One of the most interesting findings in this study was the absence of FcER
expression on y+, a+, or E+ B cells. It could be said that the expression of FceR
is restricted to g+,b+ circulating mature B cells, and that its disappearance is
correlated with the isotype switching of the B cells. The observations that FCER
is expressed only on p+,b+ cells could explain why PBL include more FcER+ cells
than found in tonsils. The loss of FccR on ,y+, a+, or e+ cells is irreversible even
in the presence of PHA-sup and IgE. However, the loss of the expression is not
due to the deletion of the gene for FcER, since RPMI-8866 cells or CESS cells,
which express IgG on their surface, also express FcER . Therefore, the situation
may be similar to the loss of S expression in the final maturation stage of B cells
that are committed to IgM secretion.
The FCER expression is not correlated with the FcyR expression. In fact,
FcyR+ B cells were observed in the a-,5- population, particularly in all a+ cells
as well as A+,b+ cell population . The result strongly suggests that FCER may have
different immunological functions from FcyR. It is interesting to note that E-
bearing cells do not have FceR even in hyper-IgE syndrome. The function of
FcER on mature B cells is yet to be defined.
Summary
The expression of FcER on human lymphocytes was studied with the anti-FcER
mAbs. FCER was expressed on most A.+,b+ circulating B cells, whereas T cells did
not express FcER even in patients with hyper-IgE syndrome. B cells with y, a, or
E phenotype did not express FcER, moreover its expression could not be induced,
suggesting that the FCER expression was correlated with isotype switching. A,+b+
B cells in bone marrow did not express FcER, but PHA-sup (supernatant from
PHA-stimulated cell cultures) could induce its expression, and the addition of
IgEaugmented this induction. Recombinant IL-2, IL-1, IFN-y or -0, or purified
B cell differentiation factor (BSF-2 B cell-stimulatory factor 2) could not induce
FceR expression in bone marrow B cells. IFN-y inhibited the FcER expression
induced by PHA-sup, suggesting that the human counterpart of BSF-I may be
responsible for FccR expression in bone marrow B cells. B cells from patients
with common variable immunodeficiency and ataxia teleangiectasia did not
expressFccR, butPHA-sup could induce itsexpression, indicating that circulating
B cells of these patients are at a differentiation stage similar to B cells in bone
marrow. The study showed that FccR is a B cell-specific differentiation marker,
the expression of which is restricted to a defined stage of B cell differentiation.
Receivedfor publication 22 April 1986 and in revisedform 10June 1986.
Note added in proof. Recent experiments with the newlycloned BSF-1 (IL-4) (Proc. Nad. Acad. Sci.
USA. 83:5894. 1986) and kindly provided by DNAX Corp., revealed that this lymphokine could
induce the expression of FceR on human bone marrow B cells, confirming our observations made
earlier in this study.1468
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